• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

scotta@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
Department of Medicine
Education
Doctoral Degree (Research) / PhD
University of Sydney
Graduate Diploma
University of Sydney
Bachelors Degree (Honours)
University of Sydney
ORCID

0000-0002-6656-295X

Prof Andrew Scott

Honorary (Professorial Fellow)
Department of Medicine

929 Scholarly works
2 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator
    DOI: 10.1016/j.ctro.2026.101200
  • 2026

    Journal article

    Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
    DOI: 10.1158/1078-0432.CCR-25-4001
  • 2026

    Journal article

    SUBDUE-3: SUB-urothelial DUrvalumab-89zirconium injEction; a phase 0 biodistribution study protocol
    DOI: 10.1111/bju.70153
  • 2026

    Journal article

    A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma.
    DOI: 10.1158/1078-0432.CCR-25-3608
  • 2026

    Journal article

    iPREDICT: Phase II study of CD8 PET in patients with immunoresponsive solid tumors—Imaging characteristics and correlation with RECIST response.
    DOI: 10.1200/jco.2026.44.16_suppl.3069
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Characterising the Plasma Proteome of Polymyalgia Rheumatica
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Application of Molecular Imaging Biomarkers in Large Vessel Vasculitis and Polymyalgia Rheumatica
Andrew Scott

Latest Honours,
Awards and Fellowships


2017
FAHMS - Fellow the Australian Academy of Health and Medical Sciences
2017
2013
FAANMS - Fellow of Australiasian Association of Nuclear Medicine Specielists
2010
Fellow of the Australian Institute of Company Directors (FAICD)

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Cancer workforce—a global crisis: a Lancet Oncology Commission
    DOI: 10.1016/S1470-2045(26)00065-3
  • 2026

    Journal article

    Phase 3 study to assess the safety and efficacy of 177 Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON).
    DOI: 10.1200/jco.2026.44.16_suppl.tps4631
  • 2026

    Journal article

    Usefulness of CAIX-targeted PET in restaging clear cell renal cell carcinoma: detection of thyroid metastasis with [89Zr]Zr-girentuximab
    DOI: 10.1016/j.eanmi.2026.100266
  • 2026

    Journal article

    Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study
    DOI: 10.1111/bjh.70468
  • 2026

    Journal article

    Health technology assessment in nuclear medicine: Challenges and opportunities in Europe
    DOI: 10.1016/j.eanmj.2026.100215

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224